Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strong financial performance with a 34% YoY revenue increase, raised 2025 guidance, and promising product launches. Despite some uncertainties in pricing and regulatory timelines, the positive financial outlook and product pipeline suggest a positive sentiment. The Q&A section reinforces confidence in future growth, with management addressing key market opportunities and revenue estimates. The overall sentiment is positive, considering the company's strategic initiatives and growth potential.
Key Financial Performance
Revenue Revenue increased more than 30% over 2024. This significant growth was driven by growing contributions from marketed medicines and disciplined investment.
TRYNGOLZA Net Product Sales TRYNGOLZA generated $50 million in net product sales in Q4 2025, reflecting a 56% increase in revenues quarter-over-quarter. Full year revenue reached $108 million. Growth was driven by strong demand, positive prescriber experiences, and effective patient access strategies.
DAWNZERA Product Sales DAWNZERA generated $8 million in product sales in 2025 from its initial few months of launch. Early adoption across all patient segments and strong participation in the free trial program contributed to this performance.
Royalty Revenues Royalty revenues increased 11% to $285 million in 2025. This growth was anchored by contributions from SPINRAZA and growing royalties from WAINUA.
R&D Revenue R&D revenue increased by more than 20% year-over-year in 2025. The largest contributor was the Sapablursen license fee, highlighting the ability to monetize noncore assets.
Total Revenue Ionis generated $944 million in total revenue in 2025, representing a 34% increase year-over-year. Revenue was split between commercial products ($436 million) and R&D collaborations ($508 million).
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TRYNGOLZA: First FDA-approved treatment for familial chylomicronemia syndrome (FCS). Exceeded expectations in its first year on the market with strong launch execution. Generated $50 million in Q4 2025 and $108 million for the full year. Expanded into Europe through partner Sobi.
DAWNZERA: FDA-approved prophylactic treatment for hereditary angioedema (HAE). Launched in August 2025 and received European approval in January 2026. Early adoption across all patient segments with strong conversion rates from free trial to paid therapy. Expected to contribute meaningfully to revenue with peak sales potential exceeding $500 million.
Olezarsen: Achieved groundbreaking Phase III results for severe hypertriglyceridemia (sHTG), showing significant reductions in triglycerides and acute pancreatitis events. Received FDA breakthrough therapy designation and submitted sNDA. Launch readiness expected by June 2026 with annual peak sales projected to exceed $2 billion.
Zilganersen: First disease-modifying treatment for Alexander disease, a rare neurodegenerative condition. Positive Phase III results and NDA submitted in January 2026. Launch expected in the second half of 2026.
Market Expansion: TRYNGOLZA expanded into Europe through partner Sobi. DAWNZERA received European approval, enabling partner Otsuka to expand access across the region. Olezarsen is preparing for a broader launch in the U.S. for sHTG, targeting over 1 million high-risk patients.
Revenue Growth: 2025 revenue increased by 34% year-over-year to $944 million, driven by marketed medicines and R&D collaborations. TRYNGOLZA and DAWNZERA contributed $108 million and $8 million, respectively, in product sales.
Financial Discipline: Maintained disciplined investment with modest expense growth. Projected 2026 operating expenses to increase in the low-teen percentage range, with revenue growing faster than expenses.
Pipeline Advancements: Multiple Phase III data readouts expected in 2026, including cardiovascular and rare disease treatments. Partnered programs like Bepirovirsen for chronic hepatitis B and pelacarsen for cardiovascular outcomes are advancing.
Strategic Shifts: Transitioned into a fully integrated commercial-stage company. Focused on expanding commercial portfolio with multiple independent launches and advancing a high-value pipeline. Targeting cash flow breakeven by 2028.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market competition: Pricing dynamics in the market are evolving, and there is a new market entrant impacting TRYNGOLZA. This could lead to pricing pressures and challenges in maintaining market share.
Regulatory risks: The sNDA for olezarsen is still under FDA review, and the company is awaiting acceptance. Delays or unfavorable decisions could impact the anticipated launch timeline and revenue projections.
Supply chain and launch readiness: The company is preparing for multiple launches, including olezarsen and zilganersen, which require significant inventory build and field team expansion. Any delays or inefficiencies in these preparations could impact launch success.
Economic uncertainties: The company is actively engaging with payers to ensure broad access to TRYNGOLZA and olezarsen. Changes in payer policies or economic conditions could affect patient access and revenue.
Strategic execution risks: Ionis is managing multiple launches and late-stage pipeline advancements simultaneously. Any missteps in execution could impact financial performance and strategic objectives.
Dependence on partnerships: Revenue from R&D collaborations and milestone payments is a significant contributor to total revenue. Delays or failures in partner programs could impact financial performance.
Financial sustainability: The company projects a non-GAAP operating loss between $500 million and $550 million for 2026, highlighting the need for disciplined financial management to achieve cash flow breakeven by 2028.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Ionis projects revenue in the range of $800 million to $825 million for 2026, representing a 20% increase over the previous year after adjusting for a one-time license fee. Commercial revenue growth is expected to be a key driver.
Product Launches: Ionis anticipates three additional launches in 2026, including two independent launches: Olezarsen for severe hypertriglyceridemia (sHTG) and Zilganersen for Alexander disease. Olezarsen is expected to achieve annual peak sales exceeding $2 billion.
Olezarsen Launch: Olezarsen is expected to launch in the fourth quarter of 2026, targeting a broad sHTG patient population. The company is preparing for a price adjustment and payer engagement to ensure broad access.
Zilganersen Launch: Zilganersen is expected to launch in the second half of 2026 for Alexander disease, with preparations underway to ensure patient access and awareness.
DAWNZERA Growth: DAWNZERA is expected to contribute meaningfully to commercial revenue growth in 2026, with steady growth anticipated as the launch progresses.
TRYNGOLZA Revenue: TRYNGOLZA revenues are expected to decline meaningfully throughout 2026 ahead of the sHTG launch, followed by accelerating growth post-launch.
Partnered Programs: Ionis expects five late-stage data readouts from partnered programs in 2026, with one positive readout already achieved. These include cardiovascular outcome trials and Phase III readouts for other indications.
Cash Flow Breakeven: Ionis remains on track to achieve cash flow breakeven by 2028, supported by accelerating revenue growth and disciplined financial management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Beth, can you clarify the guidance assumptions for sHTG sales, royalty income, and TRYNGOLZA pricing?
A:The guidance assumes sales and revenue from olezarsen in the sHTG patient population starting in Q4, with FCS-driven revenues for TRYNGOLZA until sHTG approval. Priority review could improve guidance. WAINUA is expected to grow, and there could be late-year revenues from bepirovirsen. The guidance reflects a 20% year-over-year increase on a like-for-like basis, excluding sapablursen.
Q:What is the pricing strategy for TRYNGOLZA this year?
A:Pricing discussions with payers are ongoing and confidential. The focus is on ensuring broad access for TRYNGOLZA before sHTG approval. A meaningful decline in TRYNGOLZA revenues is expected ahead of the sHTG launch, but growth is anticipated post-approval.
Q:Can you provide details on the cardio transform study regarding stabilizer use at baseline?
A:The study has a balanced baseline of patients on and not on stabilizer tafamidis, with more patients on tafamidis. Drop-ins during the study have been minimal. A baseline presentation is being prepared, but timing is not yet determined.
Q:What are the reimbursement dynamics for FCS and pricing strategy for sHTG?
A:FCS reimbursement remains strong with no meaningful competitive impact. The goal for sHTG is to maximize value and provide broad access. Pricing discussions with payers are ongoing, and the final decision is pending.
Q:What is the confidence level in the $2 billion peak revenue for olezarsen?
A:The $2 billion estimate is based on the product profile, positive Phase III data, and prescriber demand research. Confidence is bolstered by strong demand trends.
Q:What is the market opportunity for ION532 licensed to AstraZeneca?
A:ION532 targets APOL1-mediated kidney disease, a significant market opportunity. Phase I data showed strong target engagement and safety, leading to Phase II advancement. Timing of data release is up to AstraZeneca.
Q:Can you provide updates on the sHTG filing and potential for priority review?
A:The sHTG filing is on track, and the FDA is evaluating priority review. The company believes the product deserves priority review but is assuming standard review for guidance purposes.
Q:Why are there no European sites for the Angelman program, and what is the status?
A:European sites are pending regulatory approval. The company plans to open sites in Europe once approval is granted.
Q:What is the expected pricing for TRYNGOLZA in sHTG?
A:The assumed net price is approximately $20,000, consistent with the greater than $2 billion peak sales estimate.
Q:When can updates on blood-brain barrier (BBB) penetrating platforms be expected?
A:The first BBB molecule using VHH technology is in manufacturing, with IND-supporting toxicology studies expected later this year. Updates on the BBB strategy are anticipated in the second half of the year.
Q:When will functional cure rates for the GSK-partnered HBV program be available?
A:Functional cure rates will be presented at EASL in May. GSK estimates peak sales of $2.5 billion, with Ionis earning 10%-12% royalties.
Q:What is the market opportunity for Zilganersen, and how does it compare to other rare diseases?
A:Zilganersen targets Alexander disease, with approximately 300 U.S. patients. The company expects greater than $100 million in peak revenue. The launch will focus on a small number of leukodystrophy centers.
Q:What are the expectations for the HORIZON Lp(a) Phase III trial and follow-on programs?
A:The HORIZON trial is expected to confirm the Lp(a) CVD hypothesis, with results midyear. The follow-on program aims to extend dosing intervals to 6-12 months using siRNA technology.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the timing of the baseline presentation for the cardio transform study, the final decision on sHTG pricing, and the timing of European regulatory approval for the Angelman program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AP attack
Bepirovirsen
DAWNZERA
Executive VP
FCS patient
III result
NDA
RD collaboration
RNA
accelerator
acceptance
access TRYNGOLZA
approval launch
attack olezarsen
breakthrough therapy
class
contributor
conversion therapy
coverage FCS
designation FDA
disorder
enthusiasm
expansion
expense
fundamental
increase product
launch neurology
license fee
milestone payment
pancreatitis attack
people sHTG
portfolio
referral
role
royalty
sHTG approval
sHTG launch
start
stream
trial program
zilganersen
IONS Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Neutral2-26
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call highlights a strong financial performance with a 34% YoY revenue increase, raised 2025 guidance, and promising product launches. Despite some uncertainties in pricing and regulatory timelines, the positive financial outlook and product pipeline suggest a positive sentiment. The Q&A section reinforces confidence in future growth, with management addressing key market opportunities and revenue estimates. The overall sentiment is positive, considering the company's strategic initiatives and growth potential.
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
IONS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
